BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai EpimAb Biotherapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai EpimAb Biotherapeutics's
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07314294-2116@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bafisontamab: Phase 2 readout est. (NCT07314294)
DESCRIPTION:Bafisontamab\, phase 2\, Advanced Metastatic Colorectal Cancer.
 \nStudy: Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cance
 r Patients\nEstimated primary completion: 30 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bafisontamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07314294
URL:https://assetmemo.bio/drug/bafisontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
